BIPAZEN Trademark

Trademark Overview

On Friday, January 24, 2020, a trademark application was filed for BIPAZEN with the United States Patent and Trademark Office. The USPTO has given the BIPAZEN trademark a serial number of 88771717. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, February 13, 2024. This trademark is owned by KVR Pharmaceuticals Inc.. The BIPAZEN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of metabolic, hemorrhagic, endocrine, genitourinary, oncological, hepatological and hormonal related diseases and disorders
bipazen

General Information

Serial Number88771717
Word MarkBIPAZEN
Filing DateFriday, January 24, 2020
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, February 13, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 13, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of metabolic, hemorrhagic, endocrine, genitourinary, oncological, hepatological and hormonal related diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, January 28, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameKVR Pharmaceuticals Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressToronto, Ontario M5P1S2
CA
Party NameKVR Pharmaceuticals Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressToronto, Ontario M5P1S2
CA

Trademark Events

Event DateEvent Description
Tuesday, February 13, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 13, 2024PUBLISHED FOR OPPOSITION
Wednesday, January 24, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, January 11, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 10, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 10, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, January 8, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Thursday, November 30, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, November 30, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, September 6, 2023NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Wednesday, September 6, 2023INQUIRY TO SUSPENSION E-MAILED
Wednesday, September 6, 2023SUSPENSION INQUIRY WRITTEN
Thursday, March 9, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, March 9, 2023LETTER OF SUSPENSION E-MAILED
Thursday, March 9, 2023SUSPENSION LETTER WRITTEN
Wednesday, March 1, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 1, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 1, 2023TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, January 17, 2023NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Tuesday, January 17, 2023INQUIRY TO SUSPENSION E-MAILED
Tuesday, January 17, 2023SUSPENSION INQUIRY WRITTEN
Tuesday, July 19, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, July 19, 2022LETTER OF SUSPENSION E-MAILED
Tuesday, July 19, 2022SUSPENSION LETTER WRITTEN
Monday, July 18, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 18, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 18, 2022ASSIGNED TO LIE
Friday, July 15, 2022TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, January 24, 2022NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Monday, January 24, 2022INQUIRY TO SUSPENSION E-MAILED
Monday, January 24, 2022SUSPENSION INQUIRY WRITTEN
Tuesday, July 27, 2021NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, July 27, 2021LETTER OF SUSPENSION E-MAILED
Tuesday, July 27, 2021SUSPENSION LETTER WRITTEN
Thursday, July 1, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 1, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 1, 2021ASSIGNED TO LIE
Monday, May 3, 2021TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Friday, November 20, 2020NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Friday, November 20, 2020INQUIRY TO SUSPENSION E-MAILED
Friday, November 20, 2020SUSPENSION INQUIRY WRITTEN
Wednesday, May 20, 2020NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, May 20, 2020LETTER OF SUSPENSION E-MAILED
Wednesday, May 20, 2020SUSPENSION LETTER WRITTEN
Tuesday, May 19, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 19, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 19, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 14, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 14, 2020NON-FINAL ACTION E-MAILED
Tuesday, April 14, 2020NON-FINAL ACTION WRITTEN
Tuesday, April 14, 2020ASSIGNED TO EXAMINER
Tuesday, January 28, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, January 28, 2020NEW APPLICATION ENTERED

Related Keywords

bipazen hepatological oncological hormonal related disorders diseases genitourinary endocrine substances preparations